Evaluation of peritraumatic distress at the point of care: A cross-sectional study.
COVID-19
CPDI
Mental health
Pandemic
Peritraumatic distress
Journal
Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
received:
12
08
2021
revised:
22
12
2021
accepted:
24
12
2021
pubmed:
30
12
2021
medline:
12
2
2022
entrez:
29
12
2021
Statut:
ppublish
Résumé
COVID-19 related peritraumatic distress has been investigated in the general population with contrasting results probably due to the perceived risk of developing COVID-19. Our study aims to investigate this condition in individuals with ascertained or probable SARS-CoV-2 exposure. The Coronavirus Peritraumatic Distress Index (CPDI) was administered to people attending a COVID-19 point of care. The sample was stratified for perceived risk in SARS-CoV-2 positive cases, close contacts, case relatives, undergoing screening subjects, and symptomatic subjects. 1463 subjects participated, and with a mean CPDI Score of 28.2 (SD 16.9). CPDI Scores in SARS-CoV-2 positive cases were significantly higher than case relatives (p = 0.02). Multiple logistic regression revealed that having had work changes (p = 0.001), night sleep changes (p < 0.001), physical activity reduction (p = 0.002), alcohol consumption changes (p = 0.003), and at least one relative lost to COVID-19 (p < 0.001) independently predicted higher CPDI Scores. Male sex (p < 0.001), age ≥ 35 years (p < 0.001), higher educational level (p = 0.002), night sleep >7 hours (p = 0.002), and being physically active (p = 0.018) were identified as protective factors. Cross-sectional design and the regional recruitment area limit the generalizability of results. Mean CPDI values were above the threshold for medium grade peritraumatic distress, with greater CPDI Scores in subjects who tested positive for SARS-CoV-2, compared to family members or caregivers without a clear indication to undergo the swab. Specific demographics, physical and mental health events could help in identifying individuals at greater risk of COVID-19 related peritraumatic distress that may benefit from early treatment.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19 related peritraumatic distress has been investigated in the general population with contrasting results probably due to the perceived risk of developing COVID-19. Our study aims to investigate this condition in individuals with ascertained or probable SARS-CoV-2 exposure.
METHODS
METHODS
The Coronavirus Peritraumatic Distress Index (CPDI) was administered to people attending a COVID-19 point of care. The sample was stratified for perceived risk in SARS-CoV-2 positive cases, close contacts, case relatives, undergoing screening subjects, and symptomatic subjects.
RESULTS
RESULTS
1463 subjects participated, and with a mean CPDI Score of 28.2 (SD 16.9). CPDI Scores in SARS-CoV-2 positive cases were significantly higher than case relatives (p = 0.02). Multiple logistic regression revealed that having had work changes (p = 0.001), night sleep changes (p < 0.001), physical activity reduction (p = 0.002), alcohol consumption changes (p = 0.003), and at least one relative lost to COVID-19 (p < 0.001) independently predicted higher CPDI Scores. Male sex (p < 0.001), age ≥ 35 years (p < 0.001), higher educational level (p = 0.002), night sleep >7 hours (p = 0.002), and being physically active (p = 0.018) were identified as protective factors.
LIMITATIONS
CONCLUSIONS
Cross-sectional design and the regional recruitment area limit the generalizability of results.
CONCLUSIONS
CONCLUSIONS
Mean CPDI values were above the threshold for medium grade peritraumatic distress, with greater CPDI Scores in subjects who tested positive for SARS-CoV-2, compared to family members or caregivers without a clear indication to undergo the swab. Specific demographics, physical and mental health events could help in identifying individuals at greater risk of COVID-19 related peritraumatic distress that may benefit from early treatment.
Identifiants
pubmed: 34965402
pii: S0165-0327(21)01420-8
doi: 10.1016/j.jad.2021.12.101
pmc: PMC8710240
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
563-570Informations de copyright
Copyright © 2021. Published by Elsevier B.V.
Références
Rev Colomb Psiquiatr. 2021 Jul-Sep;50(3):199-213
pubmed: 34158170
J Glob Health. 2021 Mar 07;11:03004
pubmed: 34326984
World Psychiatry. 2020 Jun;19(2):129-130
pubmed: 32394569
J Clin Psychol. 2018 Sep;74(9):1457-1484
pubmed: 29543336
Riv Psichiatr. 2020 May-Jun;55(3):145-151
pubmed: 32489191
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
J Psychosom Res. 2020 Jun;133:110113
pubmed: 32354463
Aging Clin Exp Res. 2021 Jun;33(6):1729-1743
pubmed: 33999378
World Psychiatry. 2020 Jun;19(2):249-250
pubmed: 32394560
Int J Environ Res Public Health. 2021 May 14;18(10):
pubmed: 34069224
PLoS One. 2020 Dec 31;15(12):e0244809
pubmed: 33382859
Alpha Psychiatry. 2021 Sep 01;22(5):237-243
pubmed: 36447445
Addict Behav. 2020 Nov;110:106527
pubmed: 32679435
BMC Psychiatry. 2020 Oct 6;20(1):491
pubmed: 33023563
Br J Psychiatry. 2020 Sep;217(3):475-476
pubmed: 32412401
JAMA Netw Open. 2020 Sep 1;3(9):e2019686
pubmed: 32876685
J Psychiatr Res. 2021 May;137:81-88
pubmed: 33662655
Heliyon. 2020 Jun 24;6(6):e04315
pubmed: 32613133
Clin Epidemiol Glob Health. 2021 Apr-Jun;10:100708
pubmed: 33619459
Int J Environ Res Public Health. 2020 May 02;17(9):
pubmed: 32370116
World Psychiatry. 2020 Jun;19(2):261
pubmed: 32394565
Australas Psychiatry. 2020 Oct;28(5):514-516
pubmed: 32722963
Indian J Psychol Med. 2020 Jul 06;42(4):368-373
pubmed: 33398225
Clin Epidemiol Glob Health. 2021 Apr-Jun;10:100693
pubmed: 33462563
Psychiatry Res. 2021 Sep;303:114090
pubmed: 34247057
Risk Manag Healthc Policy. 2020 Jul 07;13:733-742
pubmed: 32753986
Gen Psychiatr. 2020 Mar 6;33(2):e100213
pubmed: 32215365
Br J Psychiatry. 2020 Aug;217(2):410-412
pubmed: 32362295
Am J Psychiatry. 2001 Sep;158(9):1480-5
pubmed: 11532735
PLoS One. 2021 Feb 10;16(2):e0246784
pubmed: 33566863
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
BMC Psychiatry. 2021 Jan 8;21(1):20
pubmed: 33419391
World Psychiatry. 2020 Oct;19(3):406-407
pubmed: 32931089
Psychiatr Prax. 2020 May;47(4):179-189
pubmed: 32340047
Psychol Bull. 2011 Jan;137(1):47-67
pubmed: 21090886
Lancet. 2020 Mar 14;395(10227):912-920
pubmed: 32112714
JAMA Netw Open. 2020 Jul 1;3(7):e2014053
pubmed: 32609353
Br J Psychiatry. 2020 Oct;217(4):540-542
pubmed: 32493516
Int J Environ Res Public Health. 2020 Jun 07;17(11):
pubmed: 32517294
World Psychiatry. 2021 Feb;20(1):53-54
pubmed: 33432762
Psychiatry Res. 2021 Jan;295:113599
pubmed: 33285346
Can J Psychiatry. 2012 Feb;57(2):122-9
pubmed: 22340152
Drug Alcohol Depend. 2021 Feb 1;219:108488
pubmed: 33383352
Brain Behav Immun. 2020 Jul;87:124-125
pubmed: 32360603